Alexandria is second most active early-stage life science investor
The company's venture investments and Megacampus ecosystem have catalyzed the New York City life science cluster, supporting company creation and high-value exits.
See the latest news and media coverage for Alexandria. We track all announcements, press releases, and industry mentions in real time, all in one place.
Life science–focused real estate investment trust
are.comLast updated
In short: Alexandria navigated a difficult operating environment for life sciences real estate, facing significant financial losses and leasing slowdowns.
The company's venture investments and Megacampus ecosystem have catalyzed the New York City life science cluster, supporting company creation and high-value exits.
The Science History Institute honors him for long-term impact on life sciences. The award recognizes his leadership and contributions to innovation ecosystems.
Net income per share diluted is $2.10; FFO per share diluted as adjusted is $1.73. Occupancy at 87.7%, strong leasing and liquidity reported.
This marks the fourth consecutive year, ranking second in real estate category based on U.S. survey of customer, investor, and employee trust.
Oppenheimer analysts remain bullish, citing beta and momentum, and offer buy/sell recommendations for each sector.
Morgan Stanley downgraded two life sciences REITs, Healthpeak Properties (DOC) and Alexandria Real Estate Equities (ARE), over limited visibility on lab market recovery despite some constructive data points on leasing and supply.
On June 11, 2026, Alexandria Real Estate ARE was downgraded by Morgan Stanley, with analyst Ronald Kamdem adjusting the rating from Equal-Weight to Underweight. The...
Moody’s cuts Alexandria Real Estate debt rating...
Track Alexandria and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.